1. Werner CA. The older population: 2010. 2010 Census briefs. http://www.census.gov/prod/cen2010/briefs/c2010br-09.pdf. Published November 2011. Accessed May 6, 2012.
2. Gilchrest BA. Skin aging and photoaging: an overview. J Am Acad Dermatol 1989;21:610–613.
3. Tindall JP, Smith JG Jr. Skin lesions of the aged and their association with internal changes. JAMA 1963;186:1039–1042.
4. Waller JM, Maibach HI. Age and skin structure and function, a quantitative approach (I): blood flow, pH, thickness, and ultrasound echogenicity. Skin Res Technol 2005;11(3):221–235.
5. Kligman AM. Perspectives and problems in cutaneous gerontology. J Invest Dermatol 1979;73:39–46.
6. Branchet MC, Boisnic S, Frances C, et al. Skin thickness changes in normal aging skin. Gerontology 1990;36:28–35.
7. Elias PM, Ghadially R. The aged epidermal permeability barrier: basis for functional abnormalities. Clin Geriatr Med 2002;18:103–120.
8. Chang E, Yang J, Nagavarapu U, et al. Aging and survival of cutaneous microvasculature. J Invest Dermatol 2002;118:752–758.
9. Tsuchida Y. The effect of aging and arteriosclerosis on human skin blood flow. J Dermatol Sci 1993;5:175–181.
10. Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol 2002;138:1462–1470.
11. Chung JH, Eun HC. Angiogenesis in skin aging and photoaging. J Dermatol 2007;34:593–600.
12. Reddy VP, Obrenovich ME, Atwood CS, et al. Involvement of Maillard reactions in Alzheimer disease. Neurotox Res 2002;4:191–209.
13. Walcher D, Marx N. Advanced glycation end products and C-peptide modulators in diabetic vasculopathy and atherogenesis. Semin Immunopathol 2009;31:103–111.
14. Peppa M, Uribarri J, Vlassara H. Glucose, advanced glycation end products, and diabetes complications: what is new and what works. Clin Diabetes 2003;21:186–187.
15. Pageon H. Reaction of glycation and human skin: the effects on the skin and its components, reconstructed skin as a model. Pathologie-biologie 2010;58:226–231.
16. Shah MG, Maibach HI. Estrogen and skin. An overview. Am J Clin Dermatol 2001;2:143–150.
17. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872–881.
18. Weisshaar E, Dalgard F. Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 2009;89:339–350.
19. Ward JR, Bernhard JD. Willan's itch and other causes of pruritus in the elderly. Int J Dermatol 2005;44:267–273.
20. Roberts WE. Dermatologic problems of older women. Dermatol Clin 2006;24:271–280.
21. Reich A, Stander S, Szepietowski JC. Drug-induced pruritus: a review. Acta Derm Venereol 2009;89:236–244.
22. Reich A, Stander S, Szepietowski JC. Pruritus in the elderly. Clin Dermatol 2011;29:15–23.
23. Elmariah SB, Lerner EA. Topical therapies for pruritus. Semin Cutan Med Surg 2011;30:118–126.
24. Hercogova J. Topical anti-itch therapy. Dermatol Ther 2005;18:341–343.
25. Pierard GE, Quatresooz P. What do you mean by eczema craquele? Dermatology 2007;215:3–4.
26. Sparsa A, Boulinguez S, Liozon E, et al. Predictive clinical features of eczema craquele associated with internal malignancy. Dermatology 2007;215:28–35.
27. Norman RA. Xerosis and pruritus in the elderly: recognition and management. Dermatol Ther 2003;16:254–259.
28. Rogers J, Harding C, Mayo A. Stratum corneum lipids: the effect of ageing and the seasons. Arch Dermatol Res 1996;288:765–770.
29. Rawlings VA, Watkinson, A, Rogers J, et al. Abnormalities in stratum corneum structure, lipid composition, and desmosome degradation in soap-induced winter xerosis. J Cosmet Sci 1994;45:203–220.
30. Noiles K, Vender R. Are all seborrheic keratoses benign? Review of the typical lesion and its variants. J Cutan Med Surg 2008;12:203–210.
31. Hafner C, Vogt T. Seborrheic keratosis. J Dtsch Dermatol Ges 2008;6:664–677.
32. Izikson L, Sober AJ, Mihm MC Jr, et al. Prevalence of melanoma clinically resembling seborrheic keratosis: analysis of 9204 cases. Arch Derm 2002;138:1562–1566.
33. Ramos-E-Silva M, Carvalho JC, Carneiro SC. Cutaneous paraneoplasia. Clin Derm 2011;29:541–547.
34. LCD for removal of benign skin lesions (L27362). Contractor information. http://www.medicarenhic.com/pa/policies/Removal%20of%20Benign%20Skin%20Lesions%20%28L27362%29.pdf. Accessed May 6, 2012.
35. Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc 2009;109(6 suppl 2):S13-S17.
36. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med 2007;23:615–632.
37. Farage MA, Miller KW, Berardesca E, et al. Clinical implications of aging skin: cutaneous disorders in the elderly. Am J Clin Dermatol 2009;10:73–86.
38. Christo PJ, Hobelmann G, Maine DN. Post-herpetic neuralgia in older adults: evidence-based approaches to clinical management. Drugs Aging 2007;24:1–19.
39. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305:160–166.
40. Voelker R. FDA expands age range for shingles vaccine. JAMA 2011;305:1526.
41. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271–2284.
42. Brand CU, Hunziker T, Yawalkar N, et al. IL-1 beta protein in human skin lymph does not discriminate allergic from irritant contact dermatitis. Contact Dermatitis 1996;35:152–156.
43. Buckley DA, Rycroft RJ, White IR, et al. The frequency of fragrance allergy in patch-tested patients increases with their age. Br J Dermatol 2003;149:986–989.
44. Saap L, Fahim S, Arsenault E, et al. Contact sensitivity in patients with leg ulcerations: a North American study. Arch Dermatol 2004;140:1241–1246.
45. Balato A, Balato N, Di Costanzo L, et al. Contact sensitization in the elderly. Clin Dermatol 2011;29:24–30.
46. Piaserico S, Larese F, Recchia GP, et al. Allergic contact sensitivity in elderly patients. Aging Clin Exp Res 2004;16:221–225.
47. Prakash AV, Davis MD. Contact dermatitis in older adults: a review of the literature. Am J Clin Dermatol 2010;11:373–381.
48. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev 2010;10:CD002292.
49. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011;147:286–291.
50. Kwatra SG, Jorizzo JL. Bullous pemphigoid: a case series with emphasis on long-term remission off therapy. J Dermatolog Treat 2012 March 4 [epub ahead of print].
51. Iwashita K, Matsuyama T, Akasaka E, et al. The incidence of internal malignancies in autoimmune bullous diseases. Tokai J Exp Clin Med 2007;32:42–47.
52. Song HJ, Han SH, Hong WK, et al. Paraneoplastic bullous pemphigoid: clinical disease activity correlated with enzyme-linked immunosorbent assay index for the NC16A domain of BP180. J Dermatol 2009;36:66–68.
53. Walsh SR, Hogg D, Mydlarski PR. Bullous pemphigoid: from bench to bedside. Drugs 2005;65:905–926.
54. Parker SR, Dyson S, Brisman S, et al. Mortality of bullous pemphigoid: an evaluation of 223 patients. J Am Acad Dermatol 2012;66:792–797.